

Anti-Doping Disciplinary Panel

J.L.N Stadium, Gate No. 10 Hall No.103
1st Floor, Lodhi Road, New Delhi 110 003
Telefax: 011-24368274

To,

Date: 27.12.2023

Mr. Sanjeet
R/o VPO: Dubaldhan Majra,
Jhajjar, Haryana - 124202
Email: sanjeet.joon@gmail.com

Subj: Decision of the Anti-Doping Disciplinary Panel Case No.- 125.ADDP.2023

NADA VS. MR. SANJEET (ADAMS ID – SASAMA12342)

The order containing the decision of the Anti-Doping Disciplinary Panel dated 27.12.2023 in respect of final hearing of the above case held on 13.12.2023 is enclosed.

Please note that according to Article 13.2.2 of Anti-Doping Rules of NADA 2021, **the time to file an appeal to the National Anti-Doping Appeal Panel shall be twenty-one (21) days from the date of receipt of this decision by the appealing party.** The appeal may be filed at the abovementioned address.

Also please note that according of Article 10.7.1- (**Substantial Assistance in Discovering or Establishing Anti-Doping Rule Violations**)- Any period of Ineligibility imposed may be partially suspended if you assist NADA in uncovering and/or establishing an ADRV by another Athlete or Athlete Support Personnel pursuant to Article 10.7.1 ADR. Further, the athlete is subjected to doping control test during the ineligibility period, therefore, athlete is required to update his residential address as and when changed.

Copy of the NADA Anti Doping Rules 2021 may be downloaded from NADA website at the following link:-www.nadaindia.org/en/anti-doping-rule-of-nada

The receipt of this communication may be acknowledged.

Encl: 04 sheets.



(Yasir Arafat)

Senior Programme Associate

Copy forwarded together with the copy of the order containing the decision of the Anti-Doping Disciplinary Panel for information and action deemed necessary:

1. World Anti-Doping Agency, Stock Exchange Tower, 800 Place Victoria (Suit 1700) P. O. Box 180, Montreal (Quebec), H4Z 1B7, Canada.
2. Secretary General, Athletics Federation of India, A-90, Naraina Industrial Area, Phase-1, near PVR cinema, New Delhi- 110028.
3. International Association of Athletics Federations, 17, Rue Princesse Florestine BP 359, MC 98007, Monaco.
4. National Anti-Doping Agency, J.L.N Stadium, Gate No. 10 Hall No.103, Lodhi Road, New Delhi 110003.

BEFORE THE ANTI DOPING DISCIPLINARY PANEL

In the matter of Mr. Sanjeet for violation of Articles 2.1 and 2.2
of National Anti-Doping Rules, 2021.

(PROCEEDINGS CONDUCTED THROUGH VIRTUALMODE)

Quorum: Mr. Vineet Dhanda, Chairman, ADDP
Dr. Rana Chengappa, Medical Member, ADDP
Mr. Jagbir Singh, Sports Member, ADDP

Present: Mr. Yasir Arafat, NADA
Mr. Sanjeet, Athlete
Mr. Prateek Dhanda Legal Aid Counsel for Athlete

J U D G E M E N T: **27.12.2023**

1. The present proceedings before this Anti-Doping Disciplinary Panel (“**this panel**”) emanate from 2nd Anti-Doping Rule Violations (“**ADRV**”) by Mr. Sanjeet (“**the athlete**”) of Article 2.1 and 2.2 of the NADA Anti-Doping Rules. The athlete is an “Athletics” Player and his date of birth as stated by her in the Dope Control Form (“**DCF**”), happens to be **26.01.1995**. The Athlete is a male adult National Level Athlete.

Brief Facts of the case are as follows:

2. That the Athlete namely “Sanjeet” was selected for the Doping Control Test by NADA Testing Authority during “2nd Indian Grand Prix Series 2023” in Trivandrum, Kerala. The Urine Sample Collection process was conducted on **27.03.2023** where the urine Sample of the Athlete was collected by NADA’s Dope Control Officer (DCO). That same Urine sample of the Athlete was separated into 2 parts A & B bottles with unique Code “**6501128**”.
3. A Sample of the Athlete was tested at the National Dope Testing Laboratory (NDTL) in New Delhi in accordance with the procedures set out in WADA’s International Standard for Laboratories and was returned with an Adverse Analytical Finding (“**AAF**”) for **S4. Hormone and Metabolic Modulators/ GW1516 Sulfone** origin being a non-specified substance under WADA Prohibited List of 2023.
4. That under Article 7.2.1 of ADR, the initial review of sample A showed that the Athlete did not have a Therapeutic Use Exemption (TUE); there was no apparent departure from the International Standard for Testing and Investigations (‘ISTI’) or the

International Standard for Laboratories ('ISL') that could undermine the validity of the AAF; and the AAF had not been caused by ingestion of the relevant Prohibited Substance through a permitted route.

5. That the Notification was issued to the Athlete on **26.04.2023** informing him about the AAF and that he was provisionally suspended from participating in any further sporting events till the conclusion of disciplinary proceedings pending against him. Through the said notification, the athlete was informed about his rights and that in case the athlete is unwilling to accept the result of Sample A, he has the right to request the opening of Sample B at his own cost.
6. The Athlete did not opt for the B sample analysis. Subsequently, the Notice of Charge was issued to the Athlete on **15.06.2023**.
7. That virtual hearing was conducted on 07.11.2023 & 13.12.2023 by the Hearing Panel constituted under Article 8 of NADR, 2021.

Observations and Findings of the Panel

8. We have heard the arguments made by the Athlete and his Counsel, and arguments by NADA and perused the available material on record shared with us.
9. The counsel for the athlete has confessed to violating the anti-doping rules and has requested that the athlete be granted the benefit of Rule 10.8.1. However, since this is the athlete's second violation, they would be ineligible for 7 years.
10. The panel takes notes that the Athlete in question has received a Second Anti-Doping Rule Violation (ADRV), with the earlier order dated 17.06.2021 imposing a 4-year ineligibility period for violating Articles 2.1 & 2.2 of ADR. As a result, the Athlete will be subject to the consequences outlined in Article 10.9 of ADR, 2021.
11. Article 10.9 of the National Anti-Doping Rules states that for an Athlete or other Person's second anti-doping rule violation, the period of Ineligibility shall be the greater of:
 - (a) A six (6) month period of Ineligibility; or
 - (b) A period of Ineligibility in the range between:
 - (i) the sum of the period of Ineligibility imposed for the first anti-doping rule violation plus the period of Ineligibility otherwise applicable to the second anti-doping rule violation treated as if it were a first violation, and


(ii) twice the period of Ineligibility otherwise applicable to the second anti-doping rule violation treated as if it were a first violation.

The period of Ineligibility within this range shall be determined based on the entirety of the circumstances and the Athlete or other Person's degree of Fault with respect to the second violation.

12. According to Article 10.8.1 of the NADR 2021, the Panel finds that the Athlete did not submit the Acceptance of Consequences Form within the required 20-day period following the Notice of Charge dated 15.06.2023. As a result, the Athlete is not eligible for the benefit provided under this article.
13. Based on the facts and circumstances presented, as well as the relevant rules outlined in the NADR, 2021, this panel concludes that the Athlete has violated Articles 2.1 and 2.2 of the NADR, 2021. Therefore, the Athlete is hereby sanctioned with an ineligibility period of eight (08) years under Article 10.9.1 of the NADR, 2021, the period of ineligibility shall commence from the date of his provisional suspension, i.e., 26.04.2023.
14. We also direct that under Article 10.10 all other competitive results obtained by the athlete from the date of sample collection i.e., 27.03.2023 shall be disqualified with all resulting consequences including forfeiture of medals, points, and prizes.
15. We further direct that during the period of Ineligibility, under Article 10.14.1 of the Rules, Mr. Sanjeet shall not be permitted to participate in any capacity (or assist any Athlete participating in any capacity) in a Competition, Event or other activity (other than authorised anti-doping education or rehabilitation programmes) organised, convened, authorised, or recognised by NADA or a Signatory.

The matter is disposed of, accordingly.


Dated: **27.12.2023**



Mr. Vineet Dhanda
Chairman



Dr. Rana Chengappa
Member



Jagbir Singh
Member